FORMULATION OF DIRECT COMPRESSED VERAMPAMIL SUSTAINED RELEASE FORMULATION USING OPTIMIZED CO PROCESSED EXCIPIENTS

Pharmaceutical excipients when co-processed have improved flow and disintegrant properties in tablet formulations. However, physical mixtures of excipients show limited functions, poor flow properties, and poor functional properties so they cannot be used directly in tablet formulations. Majority of solid dosage forms contain multiple excipients, which provides a wide window of opportunities by combining existing excipients to achieve the desired set of performance characteristics. Over the years, the development of single-bodied excipient combinations at a sub-particle level, called co-processed excipients which deals with particle engineering, has gained huge importance. Co-processing involves interaction of two or more excipients at the sub-particle level aimed at providing a synergy of functionality improvements, as well as masking the undesirable properties of the individual excipients. Preparation of co-processed excipients involves incorporation of one excipient into the particle structure of another, using Co-Drying and Melt granulation technology. Co-processing is primarily aimed at addressing the issues of flow ability, compressibility and disintegration potential. Co-processing of excipients is multifaceted with the characteristic properties like Absence of chemical change, Improved Flow Properties, Improved Compressibility, Better dilution potential, reduced lubricant sensitivity and multiple advantages like reducing inventory burden, reduced product cost etc.